ATE431342T1 - Inhibitoren von fettsäureamidhydrolase - Google Patents
Inhibitoren von fettsäureamidhydrolaseInfo
- Publication number
- ATE431342T1 ATE431342T1 AT03759771T AT03759771T ATE431342T1 AT E431342 T1 ATE431342 T1 AT E431342T1 AT 03759771 T AT03759771 T AT 03759771T AT 03759771 T AT03759771 T AT 03759771T AT E431342 T1 ATE431342 T1 AT E431342T1
- Authority
- AT
- Austria
- Prior art keywords
- fatty acid
- acid amide
- faah
- inhibitors
- amide hydrolase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41724702P | 2002-10-08 | 2002-10-08 | |
| PCT/US2003/031975 WO2004033652A2 (en) | 2002-10-08 | 2003-10-08 | Inhibitors of fatty acid amide hydrolase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE431342T1 true ATE431342T1 (de) | 2009-05-15 |
Family
ID=32093990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03759771T ATE431342T1 (de) | 2002-10-08 | 2003-10-08 | Inhibitoren von fettsäureamidhydrolase |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7662971B2 (de) |
| EP (2) | EP2093220A3 (de) |
| JP (1) | JP4628789B2 (de) |
| KR (1) | KR20050070041A (de) |
| CN (1) | CN1703407A (de) |
| AT (1) | ATE431342T1 (de) |
| AU (1) | AU2003275493A1 (de) |
| BR (1) | BR0314980A (de) |
| CA (1) | CA2501575A1 (de) |
| DE (1) | DE60327640D1 (de) |
| EA (1) | EA008767B1 (de) |
| ES (1) | ES2325686T3 (de) |
| MX (1) | MXPA05003762A (de) |
| WO (1) | WO2004033652A2 (de) |
| ZA (1) | ZA200501837B (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6462054B1 (en) * | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| CA2501575A1 (en) | 2002-10-08 | 2004-04-22 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| FR2865205B1 (fr) * | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866886B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique |
| DE102004039326A1 (de) * | 2004-08-12 | 2006-02-16 | Abbott Gmbh & Co. Kg | Neue medizinische Verwendungen und Verfahren |
| EP1812427A4 (de) * | 2004-10-15 | 2009-10-14 | Scripps Research Inst | Oxadiazolketone als inhibitoren von fettsäureamidhydrolase |
| WO2006074025A1 (en) | 2004-12-30 | 2006-07-13 | Janssen Pharmaceutica N.V. | Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase |
| US7541359B2 (en) | 2005-06-30 | 2009-06-02 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
| WO2007061862A2 (en) | 2005-11-18 | 2007-05-31 | Janssen Pharmaceutica N.V. | 2-keto-oxazoles as modulators of fatty acid amide hydrolase |
| EP1983994B1 (de) * | 2006-02-17 | 2015-09-30 | The Scripps Research Institute | Oxazolketone als fettsäureamidhydrolase-modulatoren |
| US9102622B2 (en) | 2006-07-28 | 2015-08-11 | University Of Connecticut | Fatty acid amide hydrolase inhibitors |
| CA2663075A1 (en) * | 2006-09-08 | 2008-03-13 | The Scripps Research Institute | Substituted oxazole ketone modulators of fatty acid amide hydrolase |
| AU2008257154B2 (en) * | 2007-05-25 | 2014-03-06 | The Scripps Research Institute | Tetracyclic inhibitors of fatty acid amide hydrolase |
| JP2010533645A (ja) * | 2007-05-31 | 2010-10-28 | ザ スクリプス リサーチ インスティテュート | 脂肪酸アミドヒドロラーゼの三環系阻害剤 |
| WO2009105220A1 (en) | 2008-02-19 | 2009-08-27 | Janssen Pharmaceutica N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| US20110184026A1 (en) * | 2008-06-19 | 2011-07-28 | Boger Dale L | C4-substituted alpha-keto oxazoles |
| WO2010005572A2 (en) * | 2008-07-09 | 2010-01-14 | The Scripps Research Institute | Alpha-keto heterocycles as faah inhibitors |
| ES2463765T3 (es) | 2008-08-04 | 2014-05-29 | Merck Sharp & Dohme Corp. | Derivados de oxazol útiles como inhibidores de la AHAG |
| US8598356B2 (en) | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| WO2010068453A1 (en) | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| BR122013027950A2 (pt) * | 2008-12-24 | 2019-12-10 | BIAL PORTELA & Cª S A | compostos farmacêuticos |
| AR076687A1 (es) * | 2009-05-18 | 2011-06-29 | Infinity Pharmaceuticals Inc | Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen |
| US8901111B2 (en) | 2009-06-05 | 2014-12-02 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
| WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
| KR101820541B1 (ko) | 2009-09-09 | 2018-02-28 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 8-옥소디히드로퓨린 유도체 |
| NO2482815T3 (de) | 2009-10-02 | 2018-09-29 | ||
| WO2011060026A1 (en) | 2009-11-12 | 2011-05-19 | Jansen Pharmaceutica Nv | Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah) |
| US20130150346A1 (en) | 2010-01-08 | 2013-06-13 | Quest Ventures Ltd. | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome |
| BR112012018913A2 (pt) * | 2010-01-28 | 2017-06-20 | Merck Sharp & Dohme | "composição farmacêutica, e, uso da composição" |
| NZ601967A (en) | 2010-03-12 | 2015-03-27 | Omeros Corp | Pde10 inhibitors and related compositions and methods |
| WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
| WO2011133444A1 (en) | 2010-04-21 | 2011-10-27 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| EP3144015B1 (de) * | 2010-09-20 | 2021-06-02 | Sirna Therapeutics, Inc. | Kationische lipide mit geringem molekulargewicht zur oligonukleotidabgabe |
| CN102964311B (zh) * | 2011-09-01 | 2016-03-09 | 大丰海嘉诺药业有限公司 | 一种合成4-甲基-5-烷氧基噁唑的方法 |
| PT2814489T (pt) * | 2012-02-17 | 2017-10-23 | Epitech Group S P A | Composições e métodos para a modulação de amidases específicas para n-aceiletanolaminas para utilização na terapia de doenças inflamatórias |
| AU2014211489A1 (en) | 2013-01-29 | 2015-08-13 | Avexxin As | Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds |
| EP3733664A1 (de) | 2013-11-01 | 2020-11-04 | Boehringer Ingelheim Animal Health USA Inc. | Antiparasitäre und pestizide isoxazolinverbindungen |
| NZ630810A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ716462A (en) | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
| WO2016160168A1 (en) * | 2015-02-20 | 2016-10-06 | Cytec Industries Inc. | Aliphatic-aromatic heterocyclic compounds and uses thereof in metal extractant compositions |
| EP3285760A4 (de) | 2015-04-24 | 2018-09-26 | Omeros Corporation | Pde10-hemmer sowie entsprechende zusammensetzungen und verfahren |
| EP3095787A1 (de) * | 2015-05-22 | 2016-11-23 | Universiteit Leiden | Pharmazeutisch aktive zusammensetzungen als dag-lipaseinhibitoren |
| JP2018535969A (ja) | 2015-11-04 | 2018-12-06 | オメロス コーポレーション | Ｐｄｅ１０阻害剤の固体状態形態 |
| GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA19269A1 (fr) * | 1980-09-16 | 1982-04-01 | Lilly Co Eli | Perfectionnement relatif a des derives de n-arylbenzamides . |
| US5821370A (en) * | 1994-10-24 | 1998-10-13 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
| TW200404789A (en) * | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
| US6462054B1 (en) * | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| US20020103192A1 (en) * | 2000-10-26 | 2002-08-01 | Curtin Michael L. | Inhibitors of histone deacetylase |
| CA2501575A1 (en) | 2002-10-08 | 2004-04-22 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
-
2003
- 2003-10-08 CA CA002501575A patent/CA2501575A1/en not_active Abandoned
- 2003-10-08 EP EP09006391A patent/EP2093220A3/de not_active Withdrawn
- 2003-10-08 BR BR0314980-3A patent/BR0314980A/pt not_active IP Right Cessation
- 2003-10-08 WO PCT/US2003/031975 patent/WO2004033652A2/en active Application Filing
- 2003-10-08 AU AU2003275493A patent/AU2003275493A1/en not_active Abandoned
- 2003-10-08 CN CNA2003801009944A patent/CN1703407A/zh active Pending
- 2003-10-08 KR KR1020057006019A patent/KR20050070041A/ko not_active Application Discontinuation
- 2003-10-08 JP JP2004543576A patent/JP4628789B2/ja not_active Expired - Fee Related
- 2003-10-08 ES ES03759771T patent/ES2325686T3/es not_active Expired - Lifetime
- 2003-10-08 US US10/528,552 patent/US7662971B2/en not_active Expired - Fee Related
- 2003-10-08 AT AT03759771T patent/ATE431342T1/de not_active IP Right Cessation
- 2003-10-08 MX MXPA05003762A patent/MXPA05003762A/es not_active Application Discontinuation
- 2003-10-08 EA EA200500633A patent/EA008767B1/ru unknown
- 2003-10-08 EP EP03759771A patent/EP1549624B1/de not_active Expired - Lifetime
- 2003-10-08 DE DE60327640T patent/DE60327640D1/de not_active Expired - Lifetime
-
2005
- 2005-03-03 ZA ZA200501837A patent/ZA200501837B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE60327640D1 (de) | 2009-06-25 |
| EP1549624A4 (de) | 2006-09-20 |
| KR20050070041A (ko) | 2005-07-05 |
| EP2093220A2 (de) | 2009-08-26 |
| JP2006502229A (ja) | 2006-01-19 |
| MXPA05003762A (es) | 2005-07-22 |
| BR0314980A (pt) | 2005-08-09 |
| US20060111359A1 (en) | 2006-05-25 |
| US7662971B2 (en) | 2010-02-16 |
| EP2093220A3 (de) | 2009-11-11 |
| EP1549624B1 (de) | 2009-05-13 |
| CA2501575A1 (en) | 2004-04-22 |
| WO2004033652A2 (en) | 2004-04-22 |
| EP1549624A2 (de) | 2005-07-06 |
| WO2004033652A3 (en) | 2004-09-16 |
| ZA200501837B (en) | 2006-06-28 |
| CN1703407A (zh) | 2005-11-30 |
| EA008767B1 (ru) | 2007-08-31 |
| EA200500633A1 (ru) | 2005-10-27 |
| AU2003275493A1 (en) | 2004-05-04 |
| ES2325686T3 (es) | 2009-09-14 |
| JP4628789B2 (ja) | 2011-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE431342T1 (de) | Inhibitoren von fettsäureamidhydrolase | |
| NO20064418L (no) | Nye amido-substituerte hydroksy-6-fenylfenantridiner | |
| CO5251452A1 (es) | Oxazoles sustituidos y derivados de tiazoles como activadores de alfa hppar | |
| EA200600509A1 (ru) | Соединения пиримидотиофена | |
| ATE427300T1 (de) | Heterocyclisch substituierte amide als calpainhemmer | |
| LU92555I2 (fr) | Empagliflozine et ses sels, en particulier Empagliflozine (*) (*) l'ingrédient actif approuvé est l'Empagliflozine de formule (1S)-1,5anhydro-1-C-{4-chloro-3-¬(4-{¬(3S)-oxolan-3-yloxyl}phényl)méthylphényl}-D-glucitol | |
| NL1027811A1 (nl) | Heterocyclische aminen als remmers 11- -hydroxy-steroïd-dehydrogenase type 1. | |
| ATE435219T1 (de) | Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase | |
| MA29029B1 (fr) | Composes de thiadiazole et leurs procedes d'utilisation | |
| NO2015002I2 (no) | Ataluren (3-[5-(2-fluorfenyl)-[ 1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav | |
| DE60217363D1 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen-abhängigen erkrankungen | |
| CY1110498T1 (el) | Παραγωγα πυραζολης ως αναστολεις των κινασων τυροσινης υποδοχεα | |
| ATE348816T1 (de) | 2,5-dioxoimidazolidin-4-ylacetamide und analoga als inhibitoren von metalloproteinase mmp12 | |
| IS7337A (is) | Nikótínamíð afleiður nytsamlegar sem P38 hindrar | |
| ATE365551T1 (de) | Fusionierte heteroaryl-derivative zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis | |
| NO20040819L (no) | Piezoelektrisk biologisk lydmonitor med kretskort. | |
| ATE494893T1 (de) | Sulfonamide, sulfamate und sulfamide als gamma- secretase-hemmer | |
| DE60313289D1 (de) | Kontrollierte synthese von ziprasidon | |
| HUP0301248A2 (hu) | Tiadiazol- és oxadiazolszármazékok, valamint foszfodiészteráz 7-gátlóként való alkalmazásuk | |
| ATE281181T1 (de) | Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren | |
| HUP0100935A2 (hu) | Amidvegyületet tartalmazó, szinergetikus hatású fungicid hatóanyag-keverék és alkalmazása | |
| NZ536103A (en) | Peptide deformylase inhibitors | |
| DK1377574T3 (da) | 6-phenylbenzonaphtyridiner | |
| EA200400716A1 (ru) | 3-(имидазолил)-2-алкоксипропионовые кислоты в качестве ингибиторов tafia (тромбин-активируемого ингибитора фибринолиза) | |
| DE50304858D1 (de) | N-'4-(2-imino-pyrrolidin-1-yl)phenyl)-acetemid-und entsprechende piperidinderivate als faktor xa inhibitoren zur behandlung von thromboembolischen erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |